Skip to content
DataLookout
Menu

OPTION-EMEANCT07349121

OPTION-EMEA Clinical Trial

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 8 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 5 → 11 locations
  2. Notable Eligibility criteria expanded, about 22 words
  3. Minor Site details revised at 1 of 5 sitesv10
  4. Minor Study sites: 3 to 5v9
  5. Notable Recruitment opened
    • Study completion pushed from Dec 2028 to Dec 2029
    • Study sites: 2 to 3
    • Start date changed from estimate of May 2026 to Jun 18, 2026
    v6
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Start date: Apr 2026 to May 2026v5
  2. Minor Study sites: 0 to 2v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Primary Safety Endpoint (PSE): Device or Procedure Related Serious Adverse Events
Timeframe: 30 days following the index procedure.
Primary Efficacy Endpoint (PEE): Acute Treatment Success
Timeframe: Through 30 days

Arms and interventions

Single arm studyOther

Subjects who meet eligibility criteria will undergo AF ablation and left atrial appendage closure using the FARAPULSE PFA system and WATCHMAN FLX Pro or WATCHMAN FLX during one interventional case.

Devices: Concomitant pulsed field ablation (PFA) and left atrial appendage closure (LAAC) during one interventional case

Procedures: Concomitant Pulsed Field Ablation and Left Atrial Appendage Closure

Sites

11 sites in 5 countries

France 3, Spain 3, Belgium 2, Italy 2, Croatia 1